Pittsburgh Life Sciences Greenhouse

Pittsburgh Life Sciences Greenhouse is a private equity and venture capital firm based in Pittsburgh, Pennsylvania, founded in 2002. The firm specializes in providing capital investments and business growth services to early-stage companies in the life sciences and biosciences sectors. Its investment focus includes biotechnology tools and services, bioinformatics, medical devices, diagnostics, healthcare information technology, and therapeutics. Pittsburgh Life Sciences Greenhouse primarily invests in companies located in Western Pennsylvania, particularly those with plans to relocate to the region. The firm typically invests between $0.1 million and $10 million, supporting emerging companies with innovative solutions in healthcare and life sciences.

Diana Cugliari

President and CEO

John B. Glicksman

VP and General Counsel

Diane Hill

Senior Investment Manager

James Jordan

President and Chief Executive Officer

Marissa Kuzirian

Investment Manager

John W. Manzetti

Executive Chairman, Founder and Managing Director, PLSG Accelerat

Philip G. Petraglia

Vice President and CFO

Delvina Smith

Director of Development and Community Engagement

Samuel Straface

Venture Partner

Alicia Varughese

Executive Associate

Alan West

Executive-in-Residence

Past deals in Pennsylvania

Forest Devices

Venture Round in 2020
Forest Devices is developing AlphaStroke, the first stroke screening device designed for use by medical personnel in any environment. A non-invasive, AI-powered device that can identify a stroke before a CT or MRI is available, AlphaStroke will improve patient outcomes by decreasing time to treatment and by increasing the overall frequency that stroke treatments are provided. Making stroke decisions smarter.

Neuro Kinetics

Funding Round in 2019
Neuro Kinetics, Inc. specializes in eye tracking technology and non-invasive neuro-otologic diagnostic testing tools, catering to audiologists, ENT specialists, neuro-otologists, neuro-ophthalmologists, and neurologists globally. Founded in 1984 and based in Pittsburgh, Pennsylvania, the company offers a range of products designed to assist medical professionals in diagnosing various diseases and conditions. Key offerings include the I-PORTAL Neuro-Otologic Test Center, which serves as a comprehensive testing solution, and the VEST software for neuro-otologic analysis. Additional products include the I-Portal Video Nystagmography and I-Portal Video Oculography systems, which facilitate vestibular diagnostics and eye tracking tests. Neuro Kinetics also provides maintenance, training, support services, and various accessories to enhance the functionality of its diagnostic tools. As of September 2019, Neuro Kinetics operates as a subsidiary of Neurolign Technologies Inc.

Clinical Platform

Funding Round in 2019
Clinical Platform creates short form, video based patient and caregiver information for people that have cancer and then connects them to clinical trials. The purpose of our business is to improve the outcomes of cancer patients by providing easily accessible and retain-able information on the diagnosis of, treatments for and living with and any type of cancer. It is a fact that better educated patients have improved outcomes.

Clinical Platform

Convertible Note in 2017
Clinical Platform creates short form, video based patient and caregiver information for people that have cancer and then connects them to clinical trials. The purpose of our business is to improve the outcomes of cancer patients by providing easily accessible and retain-able information on the diagnosis of, treatments for and living with and any type of cancer. It is a fact that better educated patients have improved outcomes.

Clinical Platform

Convertible Note in 2017
Clinical Platform creates short form, video based patient and caregiver information for people that have cancer and then connects them to clinical trials. The purpose of our business is to improve the outcomes of cancer patients by providing easily accessible and retain-able information on the diagnosis of, treatments for and living with and any type of cancer. It is a fact that better educated patients have improved outcomes.

Carmell Therapeutics

Series B in 2017
Carmell Therapeutics Corporation manufactures plasma-based biologically-active plastic medical devices from blood plasma for treating injuries to bone and connective tissue. The company’s products include REPAIR bone putty, a putty form of the plasma-based plastics to fill bone defects; and a surgical scaffold that accelerates the healing of injured tendons and ligaments for soft tissue repair. It focuses on the sports medicine market. The company was founded in 2007 and is based in Pittsburgh, Pennsylvania.

Ariel Precision Medicine

Convertible Note in 2017
Ariel Precision Medicine, Inc. operates as an integrated genomics and digital health company that provides precision medicine solutions for the diagnosis, monitoring, and treatment of complex chronic diseases and disorders. It also offers ArielDx, a cloud-based clinical decision support tool that simplifies the diagnosis and treatment of pancreatic disease. The company was incorporated in 2013 and is headquartered in Pittsburgh, Pennsylvania.

Forest Devices

Convertible Note in 2017
Forest Devices is developing AlphaStroke, the first stroke screening device designed for use by medical personnel in any environment. A non-invasive, AI-powered device that can identify a stroke before a CT or MRI is available, AlphaStroke will improve patient outcomes by decreasing time to treatment and by increasing the overall frequency that stroke treatments are provided. Making stroke decisions smarter.

Better Body Image

Seed Round in 2016
Better Body Image, Inc. is a company based in Pittsburgh, Pennsylvania, that specializes in developing a mobile application aimed at promoting health and fitness. The application, known as Better Body Image, uses proprietary data to create personalized exercise routines tailored to individual body types, activity levels, and overall goals. A key feature of the app is its patented AI technology, which allows users to visualize their appearance at their target weight, thereby enhancing motivation towards achieving fitness objectives. In collaboration with AI Ventures, the company aims to expand its reach globally, targeting one million downloads shortly after the app's launch. Better Body Image is dedicated to helping individuals manage their health and fitness journeys, leveraging a body change database that addresses chronic conditions based on waist size and body measurements.

Carmell Therapeutics

Series A in 2014
Carmell Therapeutics Corporation manufactures plasma-based biologically-active plastic medical devices from blood plasma for treating injuries to bone and connective tissue. The company’s products include REPAIR bone putty, a putty form of the plasma-based plastics to fill bone defects; and a surgical scaffold that accelerates the healing of injured tendons and ligaments for soft tissue repair. It focuses on the sports medicine market. The company was founded in 2007 and is based in Pittsburgh, Pennsylvania.

Cernostics

Series B in 2013
Cernostics is a life science company developing new molecular diagnostic tests for the fight against cancer. Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple cell types, not merely tumor cells. Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics.

Complexa

Funding Round in 2013
Complexa, Inc. is a biopharmaceutical company based in Berwyn, Pennsylvania, focused on developing therapies for severe and life-threatening diseases associated with fibrosis and inflammation. Founded in 2008, the company is advancing its lead compound, CXA-10, an oral nitrated fatty acid, for the treatment of conditions such as focal segmental glomerulosclerosis and pulmonary arterial hypertension. Complexa utilizes proprietary technology to synthesize endogenous nitro-fatty acids and related mediators, which are designed to address a range of inflammatory, fibrotic, and central nervous system diseases. These nitro-fatty acids function as cell-signaling agents that regulate key inflammatory pathways, thereby enhancing the body's natural mechanisms for resolving tissue injury and promoting repair.

Cognition Therapeutics

Venture Round in 2013
Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small molecule therapeutics aimed at addressing neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company is notable for its drug candidate CT1812, an oral brain-penetrant molecule designed to restore cellular processes disrupted by diseases such as Alzheimer’s and dry age-related macular degeneration. Cognition Therapeutics targets the toxic proteins that contribute to cognitive decline, a key factor in various degenerative diseases of the brain. The company employs proprietary assays and medicinal chemistry to create novel, high-quality drug candidates, addressing an unmet need in the treatment of these complex conditions.

ALung Technologies

Series B in 2013
ALung Technologies, Inc. is a medical device company based in Pittsburgh, Pennsylvania, specializing in the development and manufacturing of devices for treating acute respiratory failure. The company's primary product, the Hemolung Respiratory Assist System, serves as a dialysis-like alternative to mechanical ventilation by removing carbon dioxide and delivering oxygen directly into the blood. This technology allows patients' lungs to rest and recover while avoiding the need for intubation and enabling protective ventilation. In addition to the Hemolung system, ALung Technologies also develops the Hattler Catheter, which facilitates extracorporeal gas exchange by circulating blood through a small catheter inserted into the central venous bloodstream. Founded in 1997, the company focuses on innovative solutions for both acute and chronic respiratory disorders.

ATRP Solutions

Venture Round in 2013
ATRP SOLUTIONS develops and manufactures specialty polymers that meet their needs. It recognizes the polymeric materials for improving the performance of commercial products in the areas of personal care and cosmetics, detergents and surfactants, paints, pigments, coatings, and biocompatible materials. It was founded in 2006 and is headquartered in Pittsburgh, Pennsylvania.

Cognition Therapeutics

Venture Round in 2012
Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small molecule therapeutics aimed at addressing neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company is notable for its drug candidate CT1812, an oral brain-penetrant molecule designed to restore cellular processes disrupted by diseases such as Alzheimer’s and dry age-related macular degeneration. Cognition Therapeutics targets the toxic proteins that contribute to cognitive decline, a key factor in various degenerative diseases of the brain. The company employs proprietary assays and medicinal chemistry to create novel, high-quality drug candidates, addressing an unmet need in the treatment of these complex conditions.

ClearCount Medical Solutions

Debt Financing in 2012
ClearCount Medical Solutions is the only provider of a sponge management system that combines the benefits of counting and detection. Counts can be quickly reconciled and in the event of a non-reconciliation, a missing sponge can be located using the SmartWandâ„¢. ClearCount innovations bring to market a comprehensive sponge reconciliation and detection solution that improves patient safety and operational efficiency.

Complexa

Series A in 2012
Complexa, Inc. is a biopharmaceutical company based in Berwyn, Pennsylvania, focused on developing therapies for severe and life-threatening diseases associated with fibrosis and inflammation. Founded in 2008, the company is advancing its lead compound, CXA-10, an oral nitrated fatty acid, for the treatment of conditions such as focal segmental glomerulosclerosis and pulmonary arterial hypertension. Complexa utilizes proprietary technology to synthesize endogenous nitro-fatty acids and related mediators, which are designed to address a range of inflammatory, fibrotic, and central nervous system diseases. These nitro-fatty acids function as cell-signaling agents that regulate key inflammatory pathways, thereby enhancing the body's natural mechanisms for resolving tissue injury and promoting repair.

Carmell Therapeutics

Series A in 2011
Carmell Therapeutics Corporation manufactures plasma-based biologically-active plastic medical devices from blood plasma for treating injuries to bone and connective tissue. The company’s products include REPAIR bone putty, a putty form of the plasma-based plastics to fill bone defects; and a surgical scaffold that accelerates the healing of injured tendons and ligaments for soft tissue repair. It focuses on the sports medicine market. The company was founded in 2007 and is based in Pittsburgh, Pennsylvania.

Cognition Therapeutics

Series A in 2011
Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small molecule therapeutics aimed at addressing neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company is notable for its drug candidate CT1812, an oral brain-penetrant molecule designed to restore cellular processes disrupted by diseases such as Alzheimer’s and dry age-related macular degeneration. Cognition Therapeutics targets the toxic proteins that contribute to cognitive decline, a key factor in various degenerative diseases of the brain. The company employs proprietary assays and medicinal chemistry to create novel, high-quality drug candidates, addressing an unmet need in the treatment of these complex conditions.

Rinovum Women's Health

Venture Round in 2010
Rinovum Women's Health, Inc. develops medical devices for women. It offers Stork, a medical device that aids in natural fertility and conception in the privacy of home.

STARR Life Sciences

Venture Round in 2010
STARR Life Sciences Corp. specializes in the development and manufacture of research equipment for small animals, catering to life science laboratories globally. The company's product lineup includes the MouseOX Plus, a pulse oximeter that measures critical physiological parameters such as heart rate, arterial oxygen saturation, breath rate, and temperature in both anesthetized and conscious mice and rats. Additionally, STARR offers the E-Mitter Telemetry System, which enables continuous monitoring of small animals' temperature, motor activity, and heart rate, along with various related components like telemetry implants and data analysis software. Their product range also encompasses running wheels, activity cage systems, and infrared motion sensors specifically designed for rats and mice. STARR Life Sciences serves a diverse clientele, including researchers and veterinarians from universities, pharmaceutical companies, and contract research organizations. Founded in 2004, the company is headquartered in Oakmont, Pennsylvania.
Applied Computational Technologies is a software development company that specializes in applications for the life sciences, particularly in radiation treatment planning for cancer therapy. With a significant number of cancer diagnoses in the United States, a large portion of patients undergo radiation treatment, highlighting the importance of effective planning tools. The company's flagship product, ProACTive, serves as a dose calculation engine that facilitates adaptive radiotherapy, enhancing the precision and effectiveness of cancer treatment. Through its innovative software solutions, Applied Computational Technologies aims to improve patient outcomes in the challenging field of oncology.
NeuroInterventional Therapeutics, Inc. ("NIT", dba Neurointerventions, Inc.) is a Pittsburgh-based company which designs and manufactures advanced catheter systems used to find, trap, and extract thrombus ("blood clots") in a wide range of cerebral vessels, thereby increasing chances of survival and minimizing disability.

Cernostics

Series A in 2010
Cernostics is a life science company developing new molecular diagnostic tests for the fight against cancer. Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple cell types, not merely tumor cells. Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics.

Carmell Therapeutics

Seed Round in 2010
Carmell Therapeutics Corporation manufactures plasma-based biologically-active plastic medical devices from blood plasma for treating injuries to bone and connective tissue. The company’s products include REPAIR bone putty, a putty form of the plasma-based plastics to fill bone defects; and a surgical scaffold that accelerates the healing of injured tendons and ligaments for soft tissue repair. It focuses on the sports medicine market. The company was founded in 2007 and is based in Pittsburgh, Pennsylvania.

Celsense

Debt Financing in 2010
Celsense is a privately held biotechnology company offering novel MRI agents that allow scientists and clinicians to monitor the location and quantity of transplanted cells. The company's products have applications in the fields of regenerative medicine, immunotherapy, and the study of inflammation and immune system response. Celsense is currently collaborating with leading pharmaceutical and biotechnology organizations and is developing products suitable for human use.

Saladax Biomedical

Series C in 2010
Saladax Biomedical, Inc. specializes in developing and commercializing diagnostic blood tests aimed at enhancing personalized medicine in psychiatry and oncology. The company offers a range of tests under the MyCare brand, which includes MyCare Psychiatry for determining appropriate antipsychotic dosages, MyCare Oncology for optimizing chemotherapy exposure, and MyCare Neurology for assessing the impact of neurological medications. Notable products include My5-FU, MyPaclitaxel, MyDocetaxel, and MyImatinib, which assist healthcare professionals in managing treatments for various cancers and conditions. Saladax Biomedical markets its products through distributors in regions such as Asia Pacific, the European Union, the Middle East, and North Africa, as well as through direct sales in select areas. Founded in 2004 and based in Bethlehem, Pennsylvania, the company has been providing innovative diagnostic solutions for over 15 years.

Cellumen

Venture Round in 2010
Cellumen specializes in cellular systems biology solutions that enhance drug discovery and safety assessment processes for biopharmaceutical researchers. By providing advanced tools for early safety evaluation and discovery toxicology, Cellumen helps organizations improve the accuracy of predicting drug efficacy and safety, ultimately reducing failure rates and development costs. The company's innovative approach addresses the complexities of disease and safety, making it a valuable partner for leading institutions such as the Mayo Clinic, Hamamatsu Photonics K.K., the EPA, FDA, NIH, and prominent pharmaceutical companies. Through its commitment to advancing drug development, Cellumen plays a crucial role in the biopharmaceutical industry.

PeriOptimum

Seed Round in 2010
PeriOptimum provides workflow management solutions and consulting services for the healthcare industry. It offers real-time technology and process management solutions that allow hospitals to improve workflow in the operating room environment and also enables doctors, nurses, and managers to access patient location and clinical information. The company’s solution portfolio includes RealView, a real time workflow management system that allows users to see patient status in real-time and in multiple views; PeriOperative Improvement Evaluation, a process evaluation solution for on-site analysis and off-site data extraction and analysis; Surgical Analytics Services, a service to isolate, analyze, benchmark, and improve indicators; and Surgical Capacity Improvement Program, a process improvement program for the perioperative process. It also provides PeriOp Education Services, a program that enables hospitals to train their new recruits on critical topics and orient them on the hospital's perioperative department; PathFinder, an RFID-based tracking, workflow management, and communications system; and data analytics and workflow reengineering services.

ThermalTherapeuticSystems

Series A in 2009
ThermalTherapeutic Systems was founded in June, 2006 by a team of highly respected experts in the field of hyperthermic perfusion technology, medical device manufacturing, molecular diagnostics and technology commercialization.

Cognition Therapeutics

Series A in 2009
Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small molecule therapeutics aimed at addressing neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company is notable for its drug candidate CT1812, an oral brain-penetrant molecule designed to restore cellular processes disrupted by diseases such as Alzheimer’s and dry age-related macular degeneration. Cognition Therapeutics targets the toxic proteins that contribute to cognitive decline, a key factor in various degenerative diseases of the brain. The company employs proprietary assays and medicinal chemistry to create novel, high-quality drug candidates, addressing an unmet need in the treatment of these complex conditions.

Caliber Infosolutions

Seed Round in 2009
Caliber Infosolutions Inc. is Pittsburgh PA based global company, focused on solutions for Quality Management specially in Pharma and other regulated industries. Thier highly successful flagship product CaliberLIMSTM is treated as a great asset by their end users.

Saladax Biomedical

Series A in 2008
Saladax Biomedical, Inc. specializes in developing and commercializing diagnostic blood tests aimed at enhancing personalized medicine in psychiatry and oncology. The company offers a range of tests under the MyCare brand, which includes MyCare Psychiatry for determining appropriate antipsychotic dosages, MyCare Oncology for optimizing chemotherapy exposure, and MyCare Neurology for assessing the impact of neurological medications. Notable products include My5-FU, MyPaclitaxel, MyDocetaxel, and MyImatinib, which assist healthcare professionals in managing treatments for various cancers and conditions. Saladax Biomedical markets its products through distributors in regions such as Asia Pacific, the European Union, the Middle East, and North Africa, as well as through direct sales in select areas. Founded in 2004 and based in Bethlehem, Pennsylvania, the company has been providing innovative diagnostic solutions for over 15 years.

Lipella Pharmaceuticals

Seed Round in 2008
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Pittsburgh, Pennsylvania, focused on developing innovative treatments for bladder-related conditions. The company specializes in intravesical therapy, delivering localized treatments directly to the urinary bladder, and its key product candidate, LP-10 (liposomal tacrolimus), is being developed for the treatment of hemorrhagic cystitis, a painful condition often affecting cancer survivors. Additionally, Lipella is exploring therapies for interstitial cystitis, overactive bladder, and superficial bladder cancer, addressing significant unmet medical needs. The company's approach includes reformulating existing generic drugs to optimize their effectiveness for new applications. Founded in 2005, Lipella Pharmaceuticals aims to improve the quality of life for patients suffering from chronic bladder disorders.

Carmell Therapeutics

Seed Round in 2008
Carmell Therapeutics Corporation manufactures plasma-based biologically-active plastic medical devices from blood plasma for treating injuries to bone and connective tissue. The company’s products include REPAIR bone putty, a putty form of the plasma-based plastics to fill bone defects; and a surgical scaffold that accelerates the healing of injured tendons and ligaments for soft tissue repair. It focuses on the sports medicine market. The company was founded in 2007 and is based in Pittsburgh, Pennsylvania.

ParentPlus

Seed Round in 2007
ParentPlus was formed to alleviate male-factor subfertility by bringing innovative biotechnology to millions of subfertile couples for whom intra-uterine insemination (IUI) might be an appropriate therapy. This therapy, with spousal or donor sperm, is underutilized ― perhaps in part because it is not typically discussed in the popular press.

Cognition Therapeutics

Seed Round in 2007
Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small molecule therapeutics aimed at addressing neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company is notable for its drug candidate CT1812, an oral brain-penetrant molecule designed to restore cellular processes disrupted by diseases such as Alzheimer’s and dry age-related macular degeneration. Cognition Therapeutics targets the toxic proteins that contribute to cognitive decline, a key factor in various degenerative diseases of the brain. The company employs proprietary assays and medicinal chemistry to create novel, high-quality drug candidates, addressing an unmet need in the treatment of these complex conditions.

Crystalplex

Seed Round in 2007
Crystalplex Corporation develops nanocrystals for photoluminescent, electroluminescent, and photovoltaic applications. The Company’s product Sapphire quantum dots provides stable crystal design and flexible polymer matrix morphology. The company was founded in 2001 and is based in Pittsburgh, Pennsylvania.

Applied Isotope Technologies

Seed Round in 2007
Applied Isotope Technologies, Inc. specializes in providing measurement solutions for various sectors, including industrial, medical, and academic fields. The company develops and manufactures advanced analytical tools such as direct isotope dilution mass spectrometry (D-IDMS) and direct speciated isotope dilution mass spectrometry (D-SIDMS), which are designed for accurate elemental and molecular analyses. Its product offerings encompass isotopic spikes, reagent kits, and analytical standards specifically tailored for environmental testing, food safety, and biomarker detection. Additionally, Applied Isotope Technologies offers quality assurance certification, training, and technical support services to help laboratories implement precision measurement techniques. Founded in 2003 and based in Pittsburgh, Pennsylvania, the company plays a critical role in environmental toxin detection and other complex analytical challenges.

Intelomed

Pre Seed Round in 2007
InteloMed, Inc. manufactures a medical device, which measures patients' cardiovascular stability. It offers CVInsight Patient Monitoring & Informatics System, which captures a patient’s pulse waveform and processes this signal through proprietary algorithms and is used in hospitals, medical facilities, ambulatory, sub-acute, and sleep studies in the areas of hemodialysis, heart failure, and perio-operative. InteloMed, Inc. was founded in 2005 and is based in Warrendale, Pennsylvania.

ChemDAQ

Venture Round in 2007
ChemDAQ, Inc. manufactures gas detection systems for protection of personnel exposed to toxic sterilant gases. The company offers ChemDAQ sterilant gas monitoring system; and ChemDAQ data acquisition module, which provides the means of monitoring, displaying, and documenting the sterilant gas levels. It serves hospitals and various organizations. ChemDAQ, Inc. was founded in 1996 and is based in Pittsburgh, Pennsylvania.

Celsense

Pre Seed Round in 2007
Celsense is a privately held biotechnology company offering novel MRI agents that allow scientists and clinicians to monitor the location and quantity of transplanted cells. The company's products have applications in the fields of regenerative medicine, immunotherapy, and the study of inflammation and immune system response. Celsense is currently collaborating with leading pharmaceutical and biotechnology organizations and is developing products suitable for human use.

StageMark

Series B in 2007
StageMark develops and markets inflammatory diseases identification and monitoring solutions. The company's product, CB-CAPs, enables user to analyze complement products bound to various blood cell types such as erythrocytes, platelets, reticulocytes, and lymphocytes. StageMark, Inc. was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.

STARR Life Sciences

Venture Round in 2006
STARR Life Sciences Corp. specializes in the development and manufacture of research equipment for small animals, catering to life science laboratories globally. The company's product lineup includes the MouseOX Plus, a pulse oximeter that measures critical physiological parameters such as heart rate, arterial oxygen saturation, breath rate, and temperature in both anesthetized and conscious mice and rats. Additionally, STARR offers the E-Mitter Telemetry System, which enables continuous monitoring of small animals' temperature, motor activity, and heart rate, along with various related components like telemetry implants and data analysis software. Their product range also encompasses running wheels, activity cage systems, and infrared motion sensors specifically designed for rats and mice. STARR Life Sciences serves a diverse clientele, including researchers and veterinarians from universities, pharmaceutical companies, and contract research organizations. Founded in 2004, the company is headquartered in Oakmont, Pennsylvania.

Lipella Pharmaceuticals

Seed Round in 2006
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Pittsburgh, Pennsylvania, focused on developing innovative treatments for bladder-related conditions. The company specializes in intravesical therapy, delivering localized treatments directly to the urinary bladder, and its key product candidate, LP-10 (liposomal tacrolimus), is being developed for the treatment of hemorrhagic cystitis, a painful condition often affecting cancer survivors. Additionally, Lipella is exploring therapies for interstitial cystitis, overactive bladder, and superficial bladder cancer, addressing significant unmet medical needs. The company's approach includes reformulating existing generic drugs to optimize their effectiveness for new applications. Founded in 2005, Lipella Pharmaceuticals aims to improve the quality of life for patients suffering from chronic bladder disorders.
Applied Computational Technologies is a software development company that specializes in applications for the life sciences, particularly in radiation treatment planning for cancer therapy. With a significant number of cancer diagnoses in the United States, a large portion of patients undergo radiation treatment, highlighting the importance of effective planning tools. The company's flagship product, ProACTive, serves as a dose calculation engine that facilitates adaptive radiotherapy, enhancing the precision and effectiveness of cancer treatment. Through its innovative software solutions, Applied Computational Technologies aims to improve patient outcomes in the challenging field of oncology.

RedPath Integrated Pathology

Pre Seed Round in 2006
RedPath Integrated Pathology, LLC operates as a reference laboratory and provides support services for oncology cases. It offers PathFinderTG, a testing platform for resolving diagnoses from the original pathology specimen. The company serves pathologists, clinicians, and patients. RedPath Integrated Pathology, LLC was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.

Immunetrics

Seed Round in 2006
Immunetrics, Inc. develops biological models and novel tools for mechanistic modeling needs. It offers Aegis, a software platform for the model development to model developers; disease specific models; and component model libraries. The company’s modeling software includes a set of tools that make the development of models, virtual populations, and experiments, as well as the analysis of human diseases and syndromes. It also provides mechanistic and statistical modeling, and data analysis consulting services. The company was incorporated in 2003 and is based in Pittsburgh, Pennsylvania.

Applied Isotope Technologies

Seed Round in 2006
Applied Isotope Technologies, Inc. specializes in providing measurement solutions for various sectors, including industrial, medical, and academic fields. The company develops and manufactures advanced analytical tools such as direct isotope dilution mass spectrometry (D-IDMS) and direct speciated isotope dilution mass spectrometry (D-SIDMS), which are designed for accurate elemental and molecular analyses. Its product offerings encompass isotopic spikes, reagent kits, and analytical standards specifically tailored for environmental testing, food safety, and biomarker detection. Additionally, Applied Isotope Technologies offers quality assurance certification, training, and technical support services to help laboratories implement precision measurement techniques. Founded in 2003 and based in Pittsburgh, Pennsylvania, the company plays a critical role in environmental toxin detection and other complex analytical challenges.

StageMark

Venture Round in 2006
StageMark develops and markets inflammatory diseases identification and monitoring solutions. The company's product, CB-CAPs, enables user to analyze complement products bound to various blood cell types such as erythrocytes, platelets, reticulocytes, and lymphocytes. StageMark, Inc. was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.

Proteopure

Pre Seed Round in 2006
Proteopure offers protein isolation solutions for proteomic results. The company provides a universal method for isolating proteins. Its sample preparation kit uses a protein capture technology, and can specifically separate out proteins from various contaminants, including salts, nucleic acids, and detergents. Proteopure is headquartered in Pittsburgh, Pennsylvania.

Blue Belt Technologies

Pre Seed Round in 2006
Blue Belt Technologies is a medical device company that focuses on technology and capabilities of surgical instrumentation. They proprietary technology can improve minimally invasive techniques in orthopedics, providing physicians with consistency and accuracy through a myriad of intelligent hand-held tools. It also enables the development of more advanced solutions to patients’ problems. Blue Belt Technologies was acquired by Smith & Nephew on January 5m 2016. The company was founded in 2003 and is headquartered in Pennsylvania, USA.

MedSage Technologies

Pre Seed Round in 2004
medSage Technologies provides software and services which enable providers in the rapidly growing home medical equipment industry.